NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Transforming EU Pharmaceutical Legislation: EMA’s Strategic Priorities ...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicin...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...